# Extra exclusivity for sponsors who run treatment-duration and de-escalation trials

Source: https://onco.cc/ideas/idea-fund-duration-trial-exclusivity/  
OnCo record `idea-fund-duration-trial-exclusivity` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Companies lose money when they prove a shorter course works, so they never test it. Give them a modest reward, such as extra months of exclusivity, when they do.

## Summary

Regulators grant a defined exclusivity extension (for example six months, as for paediatric studies) to sponsors who complete an adequately powered randomised trial of treatment duration, stopping rules or dose de-escalation for an approved oncology drug within a set period after approval, regardless of the result. Alternatively, such trials become a condition of full approval after accelerated approval. Most immunotherapy is given for two years or until progression with no evidence for either; a legislated carrot that outweighs revenue loss from shorter courses could fix the incentive at low public cost.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A duration-trial exclusivity incentive results in at least half of newly approved immune checkpoint and targeted therapies having a completed randomised duration or de-escalation trial within five years of approval, compared with a small minority today.
- Rationale: Paediatric exclusivity created hundreds of paediatric studies that would otherwise not have happened, demonstrating industry response to modest exclusivity rewards. Duration trials such as CheckMate 153 (one year versus continuous nivolumab) and DANTE show the questions are answerable and matter to patients.
- Proposed test: Model revenue effects and legislate a pilot in one jurisdiction; count duration and de-escalation trials initiated by sponsors for drugs approved under the pilot versus before.
- Maturity: speculative
- Actor: regulator

## Sources

- Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022): https://doi.org/10.1038/d41573-022-00030-4

## Connected records

- ideas: [Patent term extension scaled to proven survival gain](https://onco.cc/ideas/idea-fund-value-based-patent-extension/), [Payers fund trials of cheaper, shorter or lower-dose versions of expensive treatments](https://onco.cc/ideas/idea-fund-payer-funded-pragmatic-trials/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/), [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- key papers: [Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape](https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-duration-trial-exclusivity.json